Editas Medicine Reports Preclinical Data Demonstrating
Preclinical data demonstrating Editas-engineered AsCas12a multiplexed editing of iPSCs enhances iNK tumor killing ability, supporting promise as a...
Stay updated with breaking news from Marks Shearman. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Preclinical data demonstrating Editas-engineered AsCas12a multiplexed editing of iPSCs enhances iNK tumor killing ability, supporting promise as a...
After falling 60% year to date, EDIT stock is finally reversing course and trending higher in morning trading.
Advancing BRILLIANCE trial of EDIT-101 for LCA10; clinical data expected by year-end RUBY trial of EDIT-301 for sickle cell disease active and recruiting Preclinical ocular data presented at ARVO supports in vivo gene editing $723 million as of March 31, 2021 CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for the first quarter of 2021. “Our team is making tremendous progress towards discovering, developing, and manufacturing novel genome editing medicine...
Published: May 05, 2021 Advancing BRILLIANCE trial of EDIT-101 for LCA10; clinical data expected by year-end RUBY trial of EDIT-301 for sickle cell disease active and recruiting Preclinical ocular data presented at ARVO supports in vivo gene editing $723 million as of March 31, 2021 CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for the first quarter of 2021. “Our team is making tremendous progress towards discovering, developing, and manufacturing nov...
Editas Medicine Names Mark S. Shearman, Ph.D., as Chief Scientific Officer May 05, 2021 06:59 ET | Source: Editas Medicine, Inc. Editas Medicine, Inc. Cambridge, Massachusetts, UNITED STATES CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it named Mark S. Shearman, Ph.D., as the Company’s Executive Vice President and Chief Scientific Officer. Dr. Shearman will join Editas Medicine in June 2021, and will lead drug discovery, research, and development f...